Freedom Broker raises IDT stock price target to $85 on strong results

IDT reported fiscal Q4 2026 revenue of $339.0 million, up 7% year over year and 6% above Freedom Broker's estimate, while gross profit and adjusted EBITDA exceeded forecasts by roughly 9% and 10%, respectively. Non-GAAP EPS rose 24% year over year to $0.94 but missed the $0.98 estimate due to higher taxes and noncontrolling-interest allocations rather than weaker operations. Management guided fiscal 2027 gross profit to $545-$555 million and adjusted EBITDA to $176-$180 million, implying midpoint growth of about 11% and 15%; Freedom Broker raised its price target to $85 from $75 while maintaining a Buy rating.

Analysis

IDT’s operating beat matters more than the modest EPS shortfall because it suggests incremental mix is flowing through higher-margin businesses rather than being purchased through price competition. The key underwriting issue is whether NRS can sustain merchant-location and payments-volume growth without a proportional increase in sales incentives; if it can, consolidated EBITDA can compound faster than revenue and support a rerating from its historically conglomerate-like valuation. Net cash also gives management flexibility for tuck-in acquisitions or further investment, but raises capital-allocation risk given the company’s multi-business structure.

The near-term setup is less attractive after the sharp move: the revised $85 target leaves limited published upside, and a single broker’s estimate revision is not sufficient evidence of broad earnings-estimate dispersion. Over the next 1-3 months, confirmation should come from analyst estimate revisions, NRS unit economics, and evidence that the smaller segments are contributing profit rather than merely meeting a management objective. Over 6-18 months, the upside case depends on IDT demonstrating that its non-NRS assets deserve either separate valuation recognition or continued margin expansion; failure would leave the stock vulnerable to multiple compression despite EBITDA growth.

Contrarian risk is that investors extrapolate an operating beat while overlooking below-the-line leakage and the difficulty of valuing minority interests across a complex corporate structure. A durable thesis requires cash conversion and per-share free-cash-flow growth, not adjusted EBITDA alone. The stock becomes more compelling on a pullback or after independently verifiable upward consensus revisions, rather than on the current post-results momentum.

Key Decisions for Investors

• Do not chase IDT above $79-$80; place it on a watchlist for entry on a pullback toward $72-$75, where a return to the revised $85 target offers roughly 1.5-2.0x upside/downside assuming a stop below $68.
• Initiate a 3-6 month long IDT only if at least two additional sell-side firms raise FY2027 EBITDA or EPS estimates and management discloses stable-to-improving NRS margin/unit economics; this would validate that the beat is repeatable rather than quarter-specific.
• Use a catalyst-driven trim discipline: reduce a long if next-quarter EBITDA falls below the implied fiscal-year run rate or if NRS growth decelerates without offsetting margin expansion; either outcome would challenge the premium multiple case.
• Avoid an options position until open interest and bid/ask spreads are checked; IDT’s smaller-cap liquidity can make listed options an inefficient expression. Cash equity with a defined stop is preferable if liquidity remains limited.